Amylyx Pharmaceuticals: Stock Sees Significant Increase Due to GLP-1 Success

After the setback with the former hope Relyvrio, Amylyx Pharmaceuticals has successfully realigned its business model towards the treatment of rare niche diseases. With the active ingredient Avexitide, the company is poised to enter a previously unoccupied billion-dollar market for post-bariatric hypoglycemia, following compelling Phase 3 study data. Thanks to a successful capital increase, the company is fully financed well into 2028 and can implement the planned commercial launch without immediate capital needs. Amylyx Pharmaceuticals...